VIVUS to Present at the BIO InvestorForum (RedNova)
MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Timothy E.

FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer (PR Newswire via Yahoo! Finance)
Genentech, Inc. announced today that the U.S. Food and Drug Administration has approved Avastin to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non- squamous, non-small cell lung cancer , the most common type of lung cancer.